KLOW 80 MG

Blend: GHK-Cu, TB-500, BPC-157, and KPV

In Stock

$129.00 usd

The KLOW 80 MG Peptide Blend combines GHK-Cu, TB-500, BPC-157, and KPV to support tissue regeneration, wound healing, and inflammation reduction in non-human test subjects, enhancing recovery and overall wellness in controlled laboratory research environments.

KLOW Blend – Research Overview
Components:
GHK-Cu – copper-binding tripeptide
TB-500 – actin-modulating peptide fragment
BPC-157 – cytoprotective gastric peptide
KPV – α-MSH–derived anti-inflammatory tripeptide
Class: Multi-pathway regenerative research blend

Research Focus: Tissue remodeling, angiogenesis, cellular migration, inflammation modulation, and epithelial/skin repair models.
The KLOW Blend combines four synergistic peptides widely studied in preclinical models for their complementary roles in cellular repair, inflammation signaling, and tissue structural organization.
All findings refer strictly to animal and cell-based research, not established human outcomes.

Component Breakdowns (Preclinical)

  1. GHK-Cu (Copper Tripeptide)
    Key Research Pathways

    • Increases collagen, elastin, and glycosaminoglycans (connective tissue components)
    • Strong antioxidant effects
    • Modulates hundreds of repair-related genes
    • Supports angiogenesis in cell models (the formation of new blood vessels)
    • Reduces inflammatory markers
    • GHK-Cu is often studied for skin and connective-tissue remodeling due to its ECM (extracellular matrix) effects.

  2. TB-500 (Thymosin Beta-4 Fragment)
    Key Research Pathways

    • Enhances actin polymerization (crucial for cell movement)
    • Increases cell migration
    • Supports angiogenesis
    • Improves structural repair in muscle/tendon models
    • Anti-inflammatory signaling
      *TB-500 is a powerful mobilizer of repair cells, moving them toward injury sites in rodent studies.

  3. BPC-157
    Key Research Pathways

    • Cytoprotection of GI, liver, vascular tissue
    • Increased fibroblast recruitment (cells that build new tissue)
    • Stabilization of vascular endothelium (The thin layer of cells that lines the inside of all your blood vessels. Think of the endothelium as:
      “The protective, intelligent lining that keeps blood vessels healthy and functioning smoothly.”)
    • Strong angiogenic activity
    • Reduced oxidative stress
    • BPC-157 is widely researched for multi-tissue regenerative signaling.

  4. KPV (Lys-Pro-Val)
    A potent anti-inflammatory tripeptide derived from α-MSH.
    Key Research Pathways

    • Downregulates TNF-α, IL-6, NF-κB
    • Supports epithelial barrier integrity (The cells that make up the outer covering or lining of surfaces in the body.)
    • Reduces inflammatory cell infiltration
    • Improves wound environment in rodent models
    • KPV is a pure anti-inflammatory signaler, complementing the structural/repair focus of the other three.

Synergistic Mechanisms (Preclinical)
The KLOW Blend addresses all phases of tissue restoration:

  1. Inflammation Reduction → (KPV + BPC-157)

    • Lowered cytokines
    • Reduced local inflammation
    • Stabilized endothelial and epithelial barriers
      (Creates a “calmer” environment for repair.)

  2. Cell Migration Support → (TB-500)

    • Actin remodeling
    • Faster movement of repair cells
    • Increased angiogenic signaling
      (Helps deliver cells to where they are needed.)

  3. Tissue Remodeling → (GHK-Cu + BPC-157)

    • Collagen production
    • Antioxidant protection
    • Improved ECM structure
    • Enhanced organization of new tissue
      (Supports the rebuilding phase.)

  4. Angiogenesis → (TB-500 + BPC-157 + GHK-Cu)

    • Increased capillary formation
    • Better nutrient/oxygen delivery
    • Improved microcirculation
      (Strong multi-peptide vascular synergy.)

Preclinical Research: Potential Applications
The KLOW blend is typically studied in:

  1. Musculoskeletal Research

    • Tendon and ligament repair markers
    • Muscle-fiber regeneration
    • Collagen deposition
    • Reduced inflammatory fibrosis
    • Improved mobility and structural integrity in rodent models

  2. Skin & Dermal Biology
    Increased collagen Type I & III

    • Improved wound closure
    • Reduced redness and inflammatory cell infiltration
    • Enhanced keratinocyte migration
    • GHK-Cu + KPV is a common pairing in dermal research.

  3. Vascular & Endothelial Studies

    • Protection against oxidative stress
    • Repair of endothelial lining
    • Better angiogenic responses

  4. GI & Mucosal Models
    (BPC-157 + KPV dominate these pathways)

    • Reduced inflammatory damage
    • Improved epithelial tight-junction formation
    • Faster mucosal repair in rodent models

  5. Systemic Inflammatory Models

    • Decreased TNF-α and IL-6 (pro-inflammatory cytokines
      (→ chemical signals that trigger inflammation in the body).
    • Reduced ROS and oxidative damage
    • Excess ROS can cause:
      oxidative stress
      cellular damage
      accelerated tissue aging
      inflammation
    • Normalized immune response patterns

Efficacy Observed in Preclinical Studies
Inflammation

  • Significant cytokine reduction
    • (Cytokines are small messenger proteins that cells release to communicate with each other during:
      inflammation,immune responses, healing,stress, injury
      Think of them as the “text messages” of the immune system.
      They tell cells: when to increase/decrease inflammation, recruit immune cells,repair tissue,fight infection
    • Less local tissue swelling
    • Reduced inflammatory infiltrates
    • Repair
    • Faster wound closure
    • Stronger collagen alignment
    • Greater fibroblast density (fibroblast=cells that build and repair connective tissue:collagen, tendons, ligaments, skin, fascia. So more connective-tissue repair cells in an area (the cells that produce collagen).
    • Increased angiogenesis
      Cellular Protection
  • Lower oxidative stress
  • Improved tissue preservation
  • Enhanced mitochondrial stability
    All findings are animal/cell-based, not confirmed in humans.

Safety & Tolerability (Preclinical)
Across available studies:

  • All four peptides demonstrate low toxicity
  • No major organ-damage signals at standard research doses
  • Good tolerability
  • No hormonal disruption
  • Long-term human PK/PD unknown
  • None of these compounds are FDA-approved.

Regulatory Status & Disclaimer

  • The KLOW blend is an investigational research formulation.
  • None of the components are approved by the FDA for therapeutic, dietary, or cosmetic use.
  • For Research Use Only.
  • Not for human consumption.
  • Not for veterinary use.
  • Not for diagnostic or therapeutic applications.
  • No medical claims are made or implied.
  • Researchers must follow all applicable laws and regulations.
Contact Us